Clinical Trial Detail

NCT ID NCT02743078
Title Optune Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors RTOG Foundation, Inc.
Indications

gliosarcoma

giant cell glioblastoma

glioblastoma multiforme

malignant glioma

Therapies

Bevacizumab

Age Groups: senior adult

No variant requirements are available.